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Abstract: The choice of inhaler device for bronchodilator reversibility is crucial since suboptimal 
inhalation technique may influence the result. On the other hand, bronchodilator response also 
varies from time to time and may depend on patient characteristics. In this study, patients with 
airway obstruction (forced expiratory volume in 1 second [FEV
1
]/forced vital capacity [FVC] 
ratio ,70% in chronic obstructive pulmonary disease [COPD]; ,80% in asthma) were included 
(n=121, age: 57.8±17.3 years). Bronchodilator reversibility (American Thoracic Society/European 
Respiratory Society criteria) was tested in patients with COPD (n=63) and asthma and COPD 
overlap syndrome (ACOS; n=12). Forty-six asthmatics served as controls. Reversibility was 
tested with 400 µg salbutamol dry powder inhaler (Buventol Easyhaler, Orion Pharma Ltd, Espoo, 
Finland). Demographic data and patients’ perceptions of Easyhaler compared with β
2
-agonist 
pressurized metered dose inhalers (pMDIs) were analyzed. American Thoracic Society/European 
Respiratory Society guideline defined reversibility was found in 21 out of 63 COPD patients 
and in two out of 12 ACOS patients. Airway obstruction was more severe in COPD patients as 
compared with controls (mean FEV
1
 and FEV
1
% predicted both P,0.0001). Average response to 
salbutamol was significantly lower in COPD patients compared with asthma controls (P,0.0001). 
Reversibility was equally often found in smokers as in never-smokers (33% vs 34%). Nonrevers-
ible COPD patients had higher mean weight, body mass index, and FEV
1
/FVC compared with 
reversible COPD patients. Most patients preferred Easyhaler and defined its use as simpler and 
more effective than use of a pMDI. Never-smokers and patients with asthma experienced Easy-
haler somewhat easier to use than smokers and patients with COPD. In conclusion, a substantial 
part of patients with COPD or ACOS showed reversibility to salbutamol dry powder inhaler. 
Nonreversible patients with COPD were characterized by higher weight and body mass index, 
and a higher FEV
1
/FVC ratio. Most patients preferred Easyhaler compared with a pMDI.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a common disease. It has been 
estimated that 23 million people in Europe are living with COPD stage II–IV and 
that 17 million have stage I disease.1 The annual cost of COPD in Europe, including 
health care costs, has been estimated to be €141 billion. Furthermore, the prevalence 
of the disease is predicted to increase until at least 2030.1
For diagnosis, patients should have a ratio between forced expiratory volume in 
1 second (FEV
1
) and forced vital capacity (FVC) of less than 70% postbronchodilator 
(,65% in patients above the age of 65 years).2,3 In recent years, it has become evident 
that several phenotypes of COPD exist.4 An additional phenotype is the asthma and 
COPD overlap syndrome (ACOS).5
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There are differences but also similarities between COPD 
and asthma.6,7 In contrast to asthma, COPD is characterized 
by airflow limitation that is not fully reversible.2 If this would 
always be true, the physiological difference between COPD 
and asthma could consequently be defined in the degree of 
reversibility of the actual airway obstruction.
In both asthma and COPD, the key diagnostic tool is mea-
surement of lung function. If airway obstruction is present, 
reversibility to a RABA should be tested. However, asthma 
patients may be nonreversible when the baseline FEV
1
 is 
close to the predicted normal value, and patients with COPD 
may show significant reversibility. The “Understanding 
Potential Long-term Impacts on Function with Tiotropium” 
study showed that at baseline 54% of the more than 5,000 
patients with moderate-to-severe COPD had a reversibility 
when tested with 80 µg ipratropium followed by 400 µg 
salbutamol of $12% and $200 mL.8 Two-thirds of the 
patients showed an improvement of $15% of FEV
1
 pre-
dicted normal.8
Many studies show that the individual COPD patient’s 
response varies from time to time and depends on patient 
characteristics.9 As a consequence, treatment guidelines  no 
longer advocate reversibility testing as part of routine assess-
ment of patients with COPD.10 ACOS is a challenging pheno-
type of obstructive airway disease with a physician diagnosis 
of both asthma and COPD. These patients may have a history 
or evidence of atopy, smoking .10 pack-years, bronchial 
hyperresponsiveness, and postbronchodilator FEV
1
 ,80% 
predicted and FEV
1
/FVC ,70%. Methacholine inhalation 
provocation test may demonstrate significant bronchocon-
striction. Bronchodilator reversibility is a key diagnostic 
feature including $15% increase in FEV
1
 or $12% and 
$200 mL increase in postbronchodilator FEV
1
 in separate 
measurements.2,11
Formulations of salbutamol include pressurized metered 
dose inhalers (pMDIs), dry powder inhalers (DPIs), and 
solutions for nebulization. It is known that choice of the 
correct inhaler device is crucial since suboptimal inhalation 
techniques can result in reduced drug delivery and efficacy 
and it should be adjusted to different patients,12 hence the 
device used for reversibility testing may influence the result. 
A meta-analysis of randomized controlled trials comparing 
the same drug delivered by different devices concluded that 
efficacy outcomes do not differ significantly, and that pMDIs 
and DPIs are equally efficacious in clinical settings,13,14 
although studies have shown that there are fewer inhalation 
errors with some DPIs.15–17 Therefore, from that point of view 
it may be an advantage to perform reversibility testing by 
using a DPI. Clinical studies have shown the DPI Easyhaler 
(Orion Pharma AB, Espoo, Finland) to be easy to use and 
preferred by patients compared with a pMDI.18,19
Aim of the study
The aim of this data analysis was to evaluate bronchodila-
tor response to salbutamol Easyhaler in patients with clini-
cally diagnosed COPD and ACOS with confirmed airway 
obstruction, and in patients with asthma. Different smoking 
habits and demographic characteristics of enrolled patients 
were analyzed. All patients received standard care for their 
obstructive lung disease. Additionally, patients’ rapid-acting 
β
2
-agonist use and perception of the easiness of salbutamol 
delivery formulations were also assessed.
Ethical approval
The study was approved by the Institutional Ethics Committee 
of the Department of Pulmonology at Semmelweis Univer-
sity. No informed consent was obtained from the participants 
as it was a noninterventional retrospective data analysis of 
real-life data collected on regular visits of the patients. No 
intervention was done for the sake of the study.
Materials and methods
study design and patients
This real-life study had a cross-sectional design and involved 
151 Caucasian outpatients or inpatients from the Department 
of Pulmonology, Semmelweis University, Budapest, Hungary. 
Patients were consecutively recruited during their regular 
visits or before discharge from the department. COPD and 
ACOS patients were included in the main analysis and asthma 
patients served as controls. All patients underwent spirometry, 
and if airway obstruction was confirmed (FEV
1
/FVC ,80% 
in asthma; ,70% in COPD), bronchodilator reversibility was 
conducted. A total of 121 patients showed airway obstruction 
at the time of the test. All patients were asked not to take regular 
bronchodilator medications 12 hours before the testing.
Male and female patients aged above 18 years were eli-
gible for inclusion in the study if: 1) they had a diagnosis of 
COPD or asthma confirmed by chest physician; 2) diagnosis 
confirmed at least 6 months before reversibility testing; 
3) they had not changed their maintenance medication within 
the last 4 weeks prior to reversibility testing; 4) they had no 
acute exacerbation within the last 4 weeks prior to reversibil-
ity testing, but could have been hospitalized for rehabilitation 
purposes. Patients were enrolled regardless of their smoking 
history or habit. Data on sex, age, diagnosis, body mass index 
(BMI), and smoking history were collected.
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spirometry measurements
Spirometry was performed using an electronic spirometer 
(PDD-301/s, Piston, Budapest, Hungary) according to the 
American Thoracic Society (ATS) guidelines.20 Data on FEV
1
, 
FVC, total lung capacity, residual volume, and airway resistance 
were collected. Lung function was also expressed as FEV
1
/
FVC and as FEV
1
% predicted normal. In cases of confirmed 
obstruction, 400 µg salbutamol delivered via the DPI Easyhaler 
(Buventol Easyhaler, Orion Pharma) was administered and 
measurements were repeated 15–20 minutes after inhalation.
Device preference for inhaled rapid-
acting β2-agonists
Patients were asked about their former use of rapid-acting 
β
2
-agonists. Patients answered questions comparing Easy-
haler DPI or classic pMDI with respect to the easiness of 
use, perceived bronchodilator effect, and effects on sputum 
expectoration.
statistical analysis
Data were analyzed with the IBM SPSS 20.0 statistical 
program package. Differences between groups were tested 
by one-way analysis of variance. Categorical variables were 
compared by chi-square test. Correlations were tested with 
Pearson’s two-tailed correlation. The level of significance 
was set at 0.05.
Logistic regression model was used to discover deeper 
relations with reversibility. The model included the follow-
ing independent variables: sex, weight (kg), BMI (kg/m2), 
smoking, and equipment (inhaler); and as the dependent 
variable: reversibility.
Results
Clinical data of the patients
A total of 151 patients with airway obstruction were tested. The 
analysis included 121 patients (72 women and 49 men) who 
had airway obstruction. There were 63 patients with COPD and 
12 with ACOS. The control group consisted of 46 patients with 
asthma. The sex distribution in relation to diagnoses is shown 
in Figure 1. The majority of the patients were outpatients. The 
patients with COPD were older (mean age 63 years) compared 
with the patients with asthma (mean age 50 years).
There were 37 (30%) current smokers, 46 (38%) ex-
smokers, and 38 never-smokers (32%). Thirty-three of the 
37 smokers (89%) had COPD. The distribution of diagnoses 
in relation to smoking habits is shown in Figure 2.
The baseline characteristics of the patients are summarized 
in Table 1. The COPD patients had significantly lower 
baseline FEV
1
, FEV
1
% predicted, and FEV
1
/FVC ratio than 
the patients with asthma. The COPD patients had higher 
mean values for airway resistance and residual volume than 
the patients with asthma. Total lung capacities did not dif-
fer between the groups. BMI mean values were similar in 
all groups.
The group of patients with ACOS was of a similar mean 
age as the patients with COPD, but had lung function values 
Figure 1 sex distribution among patients with COPD, aCOs, and asthma (%).
Abbreviations: aCOs, asthma and COPD overlap syndrome; COPD, chronic 
obstructive pulmonary disease.
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Figure 2 smoking habits among patients with COPD, aCOs, and asthma (%).
Abbreviations: aCOs, asthma and COPD overlap syndrome; COPD, chronic 
obstructive pulmonary disease.
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(FEV
1
, FEV
1
/FVC, and FEV
1
% predicted normal) very close 
to the control group of patients with asthma.
Postbronchodilator lung function
The mean lung function values of the patients after inhalation 
of 400 µg salbutamol via Easyhaler are shown in Table 2. 
The mean improvement in FEV
1
 was +0.12 L in the COPD 
group, which was significantly lower than the reversibility in 
the control asthma group (+0.26 L). In the ACOS group, the 
mean increase in FEV
1
 was exactly the same as in the asthma 
group, +0.26 L. Reversibility defined according to ATS/
European Respiratory Society (ATS/ERS) criteria was seen in 
41 patients (34%). A higher proportion of the asthma and 
COPD patients demonstrated reversibility compared with 
patients in the ACOS group (Figure 3). A total of 21 patients 
with COPD (33%) improved $12% and $200 mL in FEV
1
, 
compared with 18 patients with asthma (39%). Only two out of 
12 patients in the ACOS group (17%) showed reversibility.
Influence of clinical factors on 
reversibility
Smoking status did not influence reversibility. Approximately 
one-third of not only the never-smokers but also the active 
smokers demonstrated reversibility (Figure 4).
Table 1 Baseline characteristics and prebronchodilator lung function values in patients with COPD, aCOs, and asthma controls
Variable All (n=121) Asthma (n=46) COPD (n=63) Asthma/COPD  (n=12) Overall P-value
age 57.8±17.3 50.2±21.0 62.8±11.8# 60.8±16.5 ,0.0001
Male/female (n) 49/72 17/29 24/39 8/4 0.152
smoker: current/ex/non (n) 33/42/35 3/15/25 30/22/6 0/5/4 ,0.0001
Outpatient/inpatient (n) 87/24 37/6 43/17 7/1 0.179
Weight (kg) 74.25±16.85 75.07±17.23 72.70±16.94 79.25±14.87 0.431
height (cm) 166.78±8.79 167.59±9.94 165.75±8.06 169.08±7.66 0.356
BMI (kg/m2) 26.64±5.52 26.71±5.60 26.39±5.62 27.73±4.89 0.741
Pre-FVC (l) 2.67±1.07 3.09±1.27* 2.31±0.84 2.93±0.72 ,0.0001
Pre-FVC% predicted 79.84±19.56 88.33±19.48* 72.94±17.72 83.58±16.21 ,0.0001
Pre-FeV1 (l) 1.63±0.78 1.98±0.86* 1.32±0.61 1.93±0.56 ,0.0001
Pre-FeV1% predicted 58.97±18.61 67.93±16.71* 50.60±16.74 68.50±14.88 ,0.0001
Pre-FeV1/FVC 60.29±10.56 63.97±7.58* 56.56±11.60 65.74±7.39 ,0.0001
Pre-TlC (l) 6.13±1.24 6.17±1.32 6.11±1.26 6.08±0.76 0.965
Pre-TlC% predicted 109.64±20.46 109.95±19.52 111.03±21.76 101.25±15.50 0.316
Pre-rV (l) 3.16±1.04 2.79±0.73 3.49±1.16# 2.80±0.74 0.001
Pre-rV% predicted 157.30±52.75 150.35±48.62 167.56±55.99# 128.33±34.59 0.033
Pre-raw (kPa/s) 0.52±0.36 0.42±0.17 0.62±0.46# 0.34±0.11 0.003
Notes: Data expressed as mean ± standard deviation, if not stated otherwise. *Asthma statistically significantly greater than COPD (asthma vs COPD P,0.05). #COPD 
statistically significantly greater than asthma (COPD vs asthma P,0.05).
Abbreviations: aCOs, asthma and COPD overlap syndrome; BMI, body mass index; COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 
1 second; FVC, forced vital capacity; Pre, prebronchodilator; Post, postbronchodilator; raw, airway resistance; rV, residual volume; TlC, total lung capacity.
Table 2 lung function values after inhalation of 400 µg salbutamol via easyhaler dry powder inhaler
Variable COPD (n=63) ACOS (n=12) Controls (asthma) (n=46) Overall P-value
Post-FVC (l) 2.50±0.85 3.05±0.75 3.30±1.23* ,0.0001
Post-FVC% predicted 79.08±18.34 87.58±18.94 94.72±18.39* ,0.0001
Post-FeV1 (l) 1.44±0.65 2.05±0.57 2.24±0.96* ,0.0001
Post-FeV1% predicted 55.27±17.46 73.17±15.80 77.09±19.12* ,0.0001
Post-FeV1/FVC 56.88±11.95 67.37±7.48 67.24±8.79* ,0.0001
Post-TlC (l) 6.18±1.38 6.00±0.83 6.11±1.30 0.904
Post-TlC% predicted 112.35±21.10# 91.58±30.10 109.19±18.91 0.011
Post-rV (l) 3.41±1.21# 2.56±0.75 2.53±0.77 ,0.0001
Post-rV% predicted 161.85±51.03# 116.92±34.07 135.74±45.59 0.002
Post-raw (kPa/s) 0.45±0.28# 0.24±0.07 0.31±0.14 0.000
Notes: Data expressed as mean ± standard deviation, if not stated otherwise. *COPD statistically significantly inferior compared with asthma (asthma vs COPD P,0.05). 
#COPD statistically significantly greater than asthma (COPD vs asthma P,0.05).
Abbreviations: aCOs, asthma and COPD overlap syndrome; COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; Post, postbronchodilator; raw, airway resistance; rV, residual volume; TlC, total lung capacity.
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The logistic regression model could predict in 74% of the 
cases whether a patient was reversible or not. Only weight 
was a single significant predictor of reversibility. No other 
statistically significant or clinically important relationships 
were found.
A comparison between reversible and nonreversible 
COPD patients is shown in Table 3. The nonreversible 
COPD patients had significantly higher mean weight, BMI, 
and higher FEV
1
/FVC ratio compared with the reversible 
patients with COPD. The low sample size in the ACOS 
group did not provide enough data for a statistical com-
parison between reversible and nonreversible patients, as 
only two ACOS patients exhibited airway reversibility with 
salbutamol.
Patients’ evaluation of easyhaler dry 
powder inhaler
The majority of the patients were using an inhaled rapid-
acting bronchodilator (RABA) at the time of the study 
(Figure 5). Daily bronchodilator use was more common in 
patients with COPD than in patients with asthma.
The patients found the DPI Easyhaler easy to use and 
easier than a pMDI (Figure 6). The patients subjectively 
scored the Easyhaler device to have a greater bronchodi-
lating capacity than a pMDI, to be more effective than a 
pMDI in inducing expectoration, and in helping in morning 
activities.
Inhalator perceived differences were not influenced by 
reversibility.
Discussion
Testing of airway reversibility is an important diagnostic 
tool when investigating patients with obstructive airway 
diseases, particularly in patients with asthma. Traditionally, 
asthma has been considered a reversible airway disease in 
contrast to COPD. However, in recent years, it has been 
recognized that many patients with a clinical diagnosis of 
COPD, and without signs of asthma, may exhibit a consider-
able reversibility when tested with rapid-acting β
2
-agonists 
or anticholinergics.8 However, to know about reversibility 
when planning the treatment of patients with COPD is clini-
cally important.
It is important to emphasize that COPD patients with 
reversible airflow obstruction might also include cases 
of ACOS.11 This newly introduced entity into Global 
Initiative for Asthma and Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines is mainly 
based on clinical appearance and physician’s judgment. 
However, repeatedly measured reversibility might increase 
the number of ACOS patients in a COPD cohort and conse-
quently have impact on therapy.2 This is important because 
having ACOS predicts a low health-related quality of life21 
and these patients have a high rate of hospitalizations 
Figure 3 reversibility in patients with COPD, aCOs, and asthma (%).
Abbreviations: aCOs, asthma and COPD overlap syndrome; aTs/ers, american 
Thoracic society/european respiratory society; COPD, chronic obstructive pulmonary 
disease.
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Figure 4 reversibility in relation to smoking habits in patients with COPD, aCOs, 
and asthma (%).
Abbreviations: aCOs, asthma and COPD overlap syndrome; aTs/ers, american 
Thoracic society/european respiratory society.
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compared with patients with asthma or COPD alone.22 In 
a recent study, ACOS and COPD patients were found to 
have a similar degree of airflow limitation.23 In our study, 
baseline lung function of ACOS patients was similar to 
asthmatics and better than that of COPD patients. ACOS 
and asthmatic patients even showed similar degree of 
hyperinflation, which was milder than the hyperinflation 
detected in COPD patients. However, the explanation of 
these diverging observations cannot be stated as the mainte-
nance therapy of the three patient groups remains unknown. 
Our study showed that despite maintenance treatment 
considered to be adequate for good management of the 
patients, 121 (80%) of the originally included 151 patients 
demonstrated airway obstruction. Of these 121 patients, 
41 (34%) demonstrated reversibility according to ATS/
ERS guidelines when tested with 400 µg salbutamol via 
Easyhaler; 21 patients with COPD (33%), two with ACOS 
(17%), and 18 with asthma (39%). These figures appear 
to be low and indicate that the patients may have had a 
long-lasting airway disease with already permanent fixed 
airway obstruction. However, we do not know whether a 
different and higher percentage of reversibility would have 
Table 3 Characteristics of reversible and nonreversible patients with COPD
Variable COPD reversible COPD nonreversible P-value
age (years) 61.6 62.4 0.790
Male (n) 10 20 0.783
Female (n) 13 30 0.783
Current and ex-smokers (n) 17 44 0.969
nonsmokers (n) 2 5 0.969
Weight (kg) 64.0 77.1 0.003
height (cm) 165.4 166.7 0.564
BMI (kg/m2) 23.3 27.7 0.001
FeV1 (l) 1.38 1.62 0.188
FeV1% predicted 52.1 60.4 0.068
FeV1/FVC 53.7 62.5 0.010
FVC (l) 2.58 2.53 0.798
FVC% predicted 80.7 77.9 0.537
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
Figure 5 Patients’ use of a rapid-acting bronchodilator (raBa) at the time of the 
study in relation to diagnoses (%).
Abbreviation: COPD, chronic obstructive pulmonary disease.
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Figure 6 The patients’ experience of ease of use of easyhaler and pMDI.
Abbreviations: COPD, chronic obstructive pulmonary disease; pMDI, pressurized 
metered dose inhaler.
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been demonstrable if the patients had been tested also with 
salbutamol via a nebulizer or pMDI, due to the known 
different efficacy of different inhaler devices containing 
same active compound.24 It should also be acknowledged 
that the percentage of reversible patients only represents 
the percentage at that time point as reversibility is known 
to vary significantly from time to time both in asthma and 
COPD.2,7–9 In another recent study in patients with stable 
COPD but not receiving anti-inflammatory treatment, 31 
out of 48 patients (65%) were found to have airway revers-
ibility with salbutamol.25
Several controlled clinical studies have previously com-
pared the bronchodilating efficacy of equal single or cumula-
tive doses of salbutamol delivered via a standard pMDI and 
the DPI Easyhaler.26–29 To the best of our knowledge, this 
is the first real-life study analyzing one-time reversibility 
with the salbutamol Easyhaler in patients with COPD and 
ACOS on regular maintenance therapy for their diseases. 
The reversibility testing was performed when the patients 
visited the clinic for regular follow-up visits or just before 
they were discharged from the hospital. At the time of testing 
they did not have any new respiratory symptoms. The notable 
number of patients with reversibility in both diseases can be 
considered high in a population on regular bronchodilator 
and/or anti-inflammatory treatment.
It is obvious that an increase in FEV
1
 in a reversibility 
test of ,8% or ,150 mL are likely to be within measure-
ment variability.30,31 To understand reversibility in patients, 
it is important to know the reversibility in healthy subjects. 
In a worldwide survey (14 centers), the Burden of Obstruc-
tive Lung Disease study reported the response to inhaled 
salbutamol.32 The results indicated that an increase in FEV
1
 
of more than 300 mL is very unlikely to arise by chance. 
This equates to a 12% increase from baseline in people with 
normal lung function.33 Similar absolute changes in FEV
1
 
were also seen in the healthy comparator data reported by the 
Evaluation of COPD Longitudinally to Identify Predictive 
Surrogate Endpoints investigators.34
The definition of bronchodilator reversibility has three 
components. The first is the assessment of the short-term 
(,20 minutes after the test) change in lung function, usually 
FEV
1
, after inhalation of a RABA.35 It could be a β
2
-agonist, 
an anticholinergic agent, or both.35 Second, the change in 
FEV
1
 needs to be greater than the change that would be 
expected by chance and this is expressed as a change greater 
than 12% of the baseline value. However, if the baseline 
value is high, a large absolute change in FEV
1
 is needed for a 
positive response, but small changes close to the between-test 
variability in the measurement can be enough to suggest 
reversibility when the pretest FEV
1
 is low. To overcome this 
requirement, a third pragmatic component was added after 
the Intermittent Positive Pressure Breathing study, namely 
a requirement of at least a 200 mL absolute change.36 These 
values are now included in the ATS/ERS statement on air-
way reversibility and in the Global Initiative for Asthma and 
GOLD documents.2,33
To define actual airway obstruction in our series of 
patients, we used a fixed FEV
1
/FVC ratio of ,70% in patients 
with COPD and ,80% in patients with asthma. There is 
some controversy regarding the cutoff values for FEV
1
/
FVC in patients with COPD. Early GOLD documents used 
the ,70% cutoff, but in 2004, the ERS and ATS issued a 
statement advocating the use of the lower limit of normal 
instead of a fixed criterion.37 The lower limit of normal is 
age corrected and defined by the lower fifth percentile of 
the reference population. It can be calculated by subtracting 
1.64 times the standard deviation from the mean, that is, 
the expected value. One argument for discarding the fixed 
FEV
1
/FVC ratio of ,0.70 is that it can lead to a COPD 
diagnosis in nonsmoking elderly not having the disease.38 
Nevertheless, we used the fixed ratio as our patients had an 
established diagnosis of COPD (or asthma) and the question 
of overdiagnosing elderly was not relevant.
Easyhaler is a DPI with a consistent fine particle dose 
across a wide range of inspiratory flow rates and high lung 
deposition, and could therefore be a simple and reliable 
alternative for airway reversibility testing.39–41 It has been 
found easy to use and considered to come close to an ideal 
inhalation device by some investigators.29,42
Patients in our study expressed a preference for the use 
of Easyhaler compared with their earlier inhalation devices. 
The high acceptance of Easyhaler is in line with the results 
of previous studies, where Easyhaler has been compared with 
other devices.43 Importantly, selection of a proper inhaler 
in agreement with patients’ preferences is a key issue for 
achieving best possible control of patients with obstructive 
lung diseases.44–46
Our study has obvious limitations. We do not know the 
reversibility when, for example, a pMDI with or without 
a spacer would have been used in the same patients. The 
same is true for using an anticholinergic drug for revers-
ibility testing. We do neither know the reproducibility of the 
testing as only one test with salbutamol DPI was performed 
and the majority of the patients were used to pMDIs. If the 
percentage of patients being reversible at a specific time 
point may be constant, it only determines the percentage of 
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the population that is reversible at that time, not the response 
of the individual patient.
Thirty percent of the patients in the study were smokers, 
the majority of them having COPD. An unexpected find-
ing at the first glance was that reversibility was often seen 
equally in smokers as in never-smokers. The most logical 
explanation might be that the nonsmokers had lung function 
values close to their predicted normal values and therefore, 
reversibility was not possible to demonstrate. It is important 
to note that smokers are more often considered to have COPD 
than asthma, however, our former study confirmed that with 
more effective drug delivery, better asthma control can also 
be achieved in smokers.47
Conclusion
Our results indicate that despite ongoing maintenance 
therapy, a substantial part of patients with COPD or asthma 
showed reversibility to salbutamol DPI. This might repre-
sent undertreatment and the need to reassess maintenance 
medication. Possible cases of ACOS might also be identi-
fied. Nonreversible patients with COPD were characterized 
by higher weight and BMI and a higher FEV
1
/FVC ratio. 
Patients’ preferences of the device might increase compliance 
with treatment and adherence, so possibility to try different 
formulations of the given drugs should be offered.
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